Potassium-Competitive Acid Blocker (P-CAB) Generasi Baru: Studi Farmakologi dan Klinis Vonoprazan Fumarate
JFL : Jurnal Farmasi Lampung · 2025
DOI: 10.37090/hf4n3x55 ↗Kurz gefasst
Fachartikel in der Zeitschrift JFL : Jurnal Farmasi Lampung, 2025. Verfasst von Ade Rezki Ilahi und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The aim of this study was to determine the pharmacological profile, clinical effectiveness, and safety of Vocinti (vonoprazan fumarate) as a P-CAB class gastric acid secretion inhibitor therapy. The method used was a literature review with a qualitative-descriptive approach. Information was collected, manually sorted and critically reviewed to ensure its validity and relevance, in order to produce a comprehensive picture of the pharmacological aspects, clinical effectiveness, and safety of Vocinti use. Based on the available literature review, Vocinti (vonoprazan fumarate) as a P-CAB class gastric acid secretion inhibitor therapy shows a superior pharmacological profile compared to conventional PPIs. Vonoprazan works through reversible competitive inhibition of the H+/K+-ATPase enzyme, resulting in faster, stronger, and more consistent acid suppression, with a longer duration of action and independence from acid activation. Thus, vonoprazan is worthy of consideration as an alternative primary therapy for gastric acid disorders, especially in refractory patients or those requiring long-term therapy. Keywords: P-CAB, Vonoprazan Fumarate Clinical, Pharmacological Studies, Vocinti
Zitieren
APA
Ilahi, A. R., & Febrina, E. (2025). Potassium-Competitive Acid Blocker (P-CAB) Generasi Baru: Studi Farmakologi dan Klinis Vonoprazan Fumarate. JFL : Jurnal Farmasi Lampung. https://doi.org/10.37090/hf4n3x55
Vancouver
Ilahi AR, Febrina E. Potassium-Competitive Acid Blocker (P-CAB) Generasi Baru: Studi Farmakologi dan Klinis Vonoprazan Fumarate. JFL : Jurnal Farmasi Lampung. 2025. doi:10.37090/hf4n3x55
BibTeX
@article{Ilahi2025,
author = {Ilahi, Ade Rezki and Febrina, Ellin},
title = {Potassium-Competitive Acid Blocker (P-CAB) Generasi Baru: Studi Farmakologi dan Klinis Vonoprazan Fumarate},
journal = {JFL : Jurnal Farmasi Lampung},
year = {2025},
doi = {10.37090/hf4n3x55}
}
EUVIMED